Genomic Biopharma

Genomic Biopharma is a genomics-enabled drug discovery and development company formed in 2022 as an independent company after being incubated by Dante Genomics. The company says it is building therapies for infectious and rare diseases using genomic data mining and predictive algorithms, with a stated emphasis on RNA-based therapeutics. Public disclosures identify two early programs presented in 2022: DELLERA, a computationally designed COVID-19 vaccine candidate, and a siRNA-based therapeutic approach for megacystis-microcolon-intestinal hypoperistalsis syndrome. The company also markets itself more broadly as a provider of innovative pharmaceutical, therapeutic, and healthcare products, although its website provides limited pipeline detail. Based on available evidence, Genomic Biopharma appears to be an early-stage, preclinical biotech centered on translating large-scale genome data into personalized medicines.